Cartesian Therapeutics Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

RNAC▼

Zacks Adds Caesars Entertainment, Cartesian Therapeutics, and Insperity to Strong Sell List

Zacks Investment Research added three stocks to its Zacks Rank #5 (Strong Sell) List today. Caesars Entertainment saw its current-year earnings consensus estimate revised 104.2% downward over the last 60 days. Cartesian Therapeutics had its estimate cut by 7%, while Insperity's estimate was revised 11.6% lower over the same period.

CZR ▼NSP ▼RNAC ▼

Zacks Investment Research·57dRead more ▾